X0508 4 2025-09-29 true 0001821586 MoonLake Immunotherapeutics MLTX 0001599214 Chen Bihua C/O CORMORANT ASSET MANAGEMENT, LP 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116 true Former 10% Owner 0001583977 Cormorant Asset Management, LP 200 CLARENDON STREET 52ND FLOOR BOSTON MA 02116 true Former 10% Owner 0001618442 Cormorant Global Healthcare Master Fund, LP 200 CLARENDON STREET 52ND FLOOR BOSTON MA 02116 true Former 10% Owner 0001747677 Cormorant Private Healthcare Fund II, LP 200 CLARENDON STREET, 52ND FLOOR BOSTON MA 02116 true Former 10% Owner 0001817320 Cormorant Private Healthcare Fund III LP 200 CLARENDON STREET 52ND FLOOR BOSTON MA 02116 true Former 10% Owner 0001871297 Cormorant Private Healthcare Fund IV LP 200 CLARENDON STREET 52ND FLOOR BOSTON MA 02116 true Former 10% Owner false Class A Ordinary Shares 2025-09-29 4 S 0 70748 9.38 D 8423403 I See Footnotes Class A Ordinary Shares 2025-09-29 4 S 0 232460 8.4 D 8190943 I See Footnotes Class A Ordinary Shares 2025-09-29 4 S 0 3390943 7.58 D 4800000 I See Footnotes Class A Ordinary Shares 2025-09-29 4 S 0 2800000 6.61 D 2000000 I See Footnotes Class A Ordinary Shares 2025-09-30 4 S 0 5827 6.96 D 1994173 I See Footnotes Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $9.25 to $9.43 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund (as defined below) , Fund II (as defined below), Fund III (as defined below), Fund IV (as defined below), and the Account (as defined below). Information reported herein relates to Shares owned by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund II, LP ("Fund II"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and a managed account (the "Account" and together with the Master Fund, Fund II, Fund III and Fund IV, the "Funds")). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Funds. Cormorant Global Healthcare GP, LLC ("GP LLC"), Cormorant Private Healthcare GP II, LLC ("GP II"), Cormorant Private Healthcare GP III, LLC ("GP III") and Cormorant Private Healthcare GP IV, LLC ("GP IV") serve as General Partner of the Master Fund, Fund II, Fund III and Fund IV, respectively. Bihua Chen serves as manager of Cormorant, GP LLC, GP II, GP III and GP IV. Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such ordinary shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. Represents (i) 2,690,183 Shares beneficially owned by the Master Fund, (ii) 1,787,722 Shares beneficially owned by Fund II, (iii) 2,433,441 Shares beneficially owned by Fund III, (iv) 1,487,507 Shares beneficially owned by Fund IV, and (v) 24,550 shares beneficially owned by the Account. Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $8.20 to $9.02 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account. Represents (i) 2,615,943 Shares beneficially owned by the Master Fund, (ii) 1,738,386 Shares beneficially owned by Fund II, (iii) 2,366,285 Shares beneficially owned by Fund III, (iv) 1,446,456 Shares beneficially owned by Fund IV, and (v) 23,873 shares beneficially owned by the Account. Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $7.30 to $8.18 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account. Represents (i) 1,532,978 Shares beneficially owned by the Master Fund, (ii) 1,018,717 Shares beneficially owned by Fund II, (iii) 1,386,674 Shares beneficially owned by Fund III, (iv) 847,642 Shares beneficially owned by Fund IV, and (v) 13,989 shares beneficially owned by the Account. Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $6.20 to $7.04 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Master Fund, Fund II, Fund III, Fund IV, and the Account. Represents (i) 638,740 Shares beneficially owned by the Master Fund, (ii) 424,466 Shares beneficially owned by Fund II, (iii) 577,783 Shares beneficially owned by Fund III, (iv) 353,184 Shares beneficially owned by Fund IV, and (v) 5,827 shares beneficially owned by the Account. Represents the weighted average sale price of Class A Ordinary Shares ("Shares") sold in a series of open market transactions on the transaction date at prices ranging from $6.94 to $6.99 per Share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of Shares sold at each price. All of these Shares were sold by the Account. Represents (i) 638,740 Shares beneficially owned by the Master Fund, (ii) 424,466 Shares beneficially owned by Fund II, (iii) 577,783 Shares beneficially owned by Fund III, and (iv) 353,184 Shares beneficially owned by Fund IV. /s/ Bihua Chen 2025-10-01 /s/ CORMORANT ASSET MANAGEMENT, LP By: Cormorant Asset Management GP, LLC, its General Partner, By: Bihua Chen, Managing Member 2025-10-01 /s/ CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP, By: Cormorant Global Healthcare GP, LLC, its General Partner By: Bihua Chen, Managing Member 2025-10-01 /s/ CORMORANT PRIVATE HEALTHCARE FUND II, LP By: Cormorant Private Healthcare GP II, LLC, its General Partner By: Bihua Chen, Managing Member 2025-10-01 /s/ CORMORANT PRIVATE HEALTHCARE FUND III, LP By: Cormorant Private Healthcare GP III, LLC, its General Partner By: Bihua Chen, Managing Member 2025-10-01 /s/ CORMORANT PRIVATE HEALTHCARE FUND IV, LP By: Cormorant Private Healthcare GP IV, LLC, its General Partner By: Bihua Chen, Managing Member 2025-10-01